Bionano Genomics 8-K Report: Key Updates from December 31, 2024
Based on the provided financial report section, here are the key points extracted:
- Company Information:
- Name: Bionano Genomics, Inc.
- CIK (Central Index Key): 0001411690
- SEC File Number: 001-38613
- EIN (Employer Identification Number): 26-1756290
- Address: 9540 Towne Centre Drive, Suite 100, San Diego, CA 92121
- Phone Number: 858-888-7600
- Filing Type:
- Form: 8-K (Current Report)
- Filing Date:
- Date of Report: December 31, 2024
- Securities Information:
- Common Stock:
- Par Value: $0.0001
- Ticker Symbol: BNGO
- Exchange: NASDAQ
- Period of Reporting:
- Start Date: December 31, 2024
- End Date: December 31, 2024
Insights:
- The report appears to be a current report (8-K), which typically provides information that is of immediate interest to shareholders and the investing public.
- The date indicates that this filing may include recent significant events or changes that occurred on or prior to December 31, 2024.
- The company operates in the biotechnology space, focusing on genomics, which could indicate relevance for developments in health and medical research.
- The listing on NASDAQ suggests a level of credibility and access to capital markets, while the par value of the common stock indicates a low nominal value, common in startup and growth-oriented biotech firms.
This summary outlines the crucial elements from the filing and provides context for potential implications in the biotech industry.